(NASDAQ: APVO) Aptevo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.38%.
Aptevo Therapeutics's earnings in 2026 is -$27,924,000.On average, 4 Wall Street analysts forecast APVO's earnings for 2026 to be -$29,678,483, with the lowest APVO earnings forecast at -$29,467,143, and the highest APVO earnings forecast at -$29,530,819. On average, 4 Wall Street analysts forecast APVO's earnings for 2027 to be -$15,404,848, with the lowest APVO earnings forecast at -$26,206,585, and the highest APVO earnings forecast at -$3,637,380.
In 2028, APVO is forecast to generate -$12,964,476 in earnings, with the lowest earnings forecast at -$22,030,140 and the highest earnings forecast at -$3,087,848.